Aclaris Therapeutics (ACRS) Stock Rating Lowered by Zacks Investment Research
Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
A number of other analysts have also issued reports on ACRS. BidaskClub upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. ValuEngine lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. JMP Securities restated an “outperform” rating and issued a $39.00 price target on shares of Aclaris Therapeutics in a research note on Friday, September 8th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $50.00 price target on shares of Aclaris Therapeutics in a research note on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Aclaris Therapeutics presently has a consensus rating of “Hold” and an average price target of $39.20.
Shares of Aclaris Therapeutics (NASDAQ ACRS) traded up $0.28 during trading hours on Wednesday, hitting $24.19. 308,600 shares of the company were exchanged, compared to its average volume of 306,833. The company has a market capitalization of $737.26, a price-to-earnings ratio of -11.20 and a beta of 1.96. Aclaris Therapeutics has a fifty-two week low of $21.32 and a fifty-two week high of $33.25.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.23. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $2.00 million. equities analysts predict that Aclaris Therapeutics will post -2.59 earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. boosted its holdings in Aclaris Therapeutics by 55.4% in the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after purchasing an additional 697,104 shares during the period. FMR LLC boosted its holdings in Aclaris Therapeutics by 14.6% in the second quarter. FMR LLC now owns 1,896,206 shares of the biotechnology company’s stock worth $51,425,000 after purchasing an additional 242,269 shares during the period. Eagle Asset Management Inc. boosted its holdings in Aclaris Therapeutics by 1.7% in the third quarter. Eagle Asset Management Inc. now owns 1,380,549 shares of the biotechnology company’s stock worth $36,446,000 after purchasing an additional 22,576 shares during the period. Westfield Capital Management Co. LP boosted its holdings in Aclaris Therapeutics by 79.6% in the second quarter. Westfield Capital Management Co. LP now owns 1,249,254 shares of the biotechnology company’s stock worth $33,880,000 after purchasing an additional 553,752 shares during the period. Finally, Point72 Asset Management L.P. boosted its holdings in Aclaris Therapeutics by 3.5% in the third quarter. Point72 Asset Management L.P. now owns 892,298 shares of the biotechnology company’s stock worth $23,030,000 after purchasing an additional 29,896 shares during the period. 92.02% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/aclaris-therapeutics-acrs-stock-rating-lowered-by-zacks-investment-research/1795620.html.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.